Intellia Therapeutics, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This filing reports full-year results; standalone fourth-quarter financial results are not clearly provided in the supplied text. Intellia is a clinical-stage gene-editing company with no approved products or product-sale revenue.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Collaboration revenue | $36.3 million | $52.1 million |
| Research and development expense | $435.1 million | $420.0 million |
| General and administrative expense | $116.5 million | $90.3 million |
| Total operating expenses | $551.6 million | $510.3 million |
| Operating loss | $(515.3) million | $(458.2) million |
| Net loss | $(481.2) million | $(474.2) million |
| Net loss per share, basic and diluted | $(5.42) | $(6.16) |
| Net cash used in operating activities | $(394.1) million | $(333.3) million |
- Collaboration revenue was the company’s only reported revenue; it fell 30% year over year. The filing reports no product sales. Operating and profit margins are not meaningful indicators for this loss-making development-stage business.
- Net loss increased by $7.0 million despite higher interest income. Interest income rose to $49.8 million from $8.5 million, partly offsetting the larger operating loss and equity-method investment losses.
- At year-end, cash and cash equivalents were $226.7 million and marketable securities were $785.3 million, including $99.9 million classified as noncurrent. Together these totaled $1,012.1 million. The cash-flow statement separately reports $240.4 million of cash, cash equivalents and restricted cash, including $13.6 million of restricted cash.
- Total liabilities were $250.8 million, including $115.3 million of operating lease liabilities and $61.0 million of deferred revenue. The filing reports no borrowings or other financial debt.
- Financing activities provided $130.3 million, primarily from $119.8 million of net ATM offering proceeds. The company issued 4.1 million shares under its 2022 ATM agreement during 2023; $79.0 million of capacity remained at year-end.
Material changes and business developments
- Research and development expense rose 4% to $435.1 million. Higher spending on NTLA-2001, NTLA-2002 and NTLA-3001, personnel, facilities and stock-based compensation was partly offset by the discontinued NTLA-5001 program and the absence of 2022 Rewrite acquisition-related in-process R&D expense.
- General and administrative expense increased 29%, primarily due to employee-related costs, including stock-based compensation.
- Regeneron’s extension of its technology collaboration to April 2026 caused a $10.3 million cumulative catch-up reduction to 2023 revenue. Regeneron’s $30.0 million nonrefundable extension payment was due in April 2024.
- The company paid a $25.0 million Rewrite research milestone in February 2023, settling it with $0.9 million in cash and 567,045 shares.
- Year-end shares outstanding were 93.0 million, versus 87.1 million a year earlier. The company reported $134.1 million in stock-based compensation expense for 2023.
Outlook, risks and unusual items
- Management estimated that year-end cash, cash equivalents and marketable securities, together with collaboration research and cost-reimbursement funding, would support operations into mid-2026. This estimate excludes potential milestone payments and certain strategic uses of capital, and depends on assumptions that may prove inaccurate.
- Management expects 2024 R&D expense to increase as it advances pivotal trials for NTLA-2001 and NTLA-2002, progresses NTLA-3001 and nominates additional candidates. In January 2024, Intellia announced a roughly 15% workforce reduction and a pause in selected exploratory research programs to focus resources on strategic priorities.
- NTLA-2001: the global Phase 3 MAGNITUDE trial in ATTR cardiomyopathy was enrolling; management expected to dose its first patient in Q1 2024 and was preparing a separate pivotal study in ATTR polyneuropathy for 2024. Interim Phase 1 data from 62 patients treated at doses of at least 0.3 mg/kg showed median serum TTR reduction of 91% at day 28. These are interim results, not proof of approval or long-term clinical benefit.
- NTLA-2002: Phase 2 enrollment and dosing were completed in January 2024. Management expected to use those data to select a Phase 3 dose and planned to initiate a global pivotal study in the second half of 2024, subject to regulatory feedback. Earlier Phase 1 interim data showed a 95% mean reduction in monthly HAE attack rate across 10 patients; follow-up and trial size remain limited.
- NTLA-3001: a clinical trial application was submitted in December 2023, and management planned to dose the first patient in 2024. The filing also notes FDA clearance of Regeneron’s hemophilia B gene-insertion IND in February 2024, with a Phase 1 study expected to begin mid-2024.
- Key risks include uncertain clinical efficacy and safety, potential unintended genome edits or immune reactions, manufacturing and trial-enrollment challenges, regulatory uncertainty, dependence on collaborators and external suppliers, and the need for future capital. Intellectual-property disputes are a notable risk: the PTAB found Broad had priority over the UC/Vienna/Charpentier family in a U.S. interference; appeals were pending, and related ToolGen and Sigma-Aldrich proceedings could affect rights.
- Other commitments include $146.5 million of commenced lease payments and at least $146.0 million for the Waltham facility lease, expected to commence in the second half of 2024. Future milestone and royalty obligations are uncertain and are not included in those totals. No significant new litigation or material litigation changes were reported for 2023.
- Subsequent to year-end, Intellia announced a February 2024 collaboration with ReCode Therapeutics to research CRISPR-based cystic fibrosis medicines. ReCode is to lead subsequent preclinical and clinical development and certain commercialization; Intellia may receive milestones and royalties.
Important facts for investors to verify
- Review the complete audited statements and notes for cash availability, securities maturity and classification, collaboration receivables, deferred revenue, lease commitments and any restrictions on cash.
- Track actual operating cash use against management’s mid-2026 runway estimate, including the effects of the workforce reduction, trial spending, facility build-out and collaboration funding.
- Verify enrollment, dose selection, safety, durability and clinically meaningful outcomes in the pivotal NTLA-2001 and NTLA-2002 trials; distinguish interim biomarker or attack-rate results from confirmatory evidence.
- Monitor whether planned trial and dosing timelines are achieved, including regulatory feedback, NTLA-3001 initiation and the hemophilia B collaboration program.
- Assess dilution and remaining ATM capacity, collaboration economics and milestone timing, the AvenCell investment’s potential impairment, and developments in CRISPR intellectual-property proceedings.
The independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting; management and the auditor concluded controls were effective as of December 31, 2023.